Cardiology Online - International Academy of Cardiology
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Discussion Groups
   Job Opportunities
   Contact Us





20th World Congress on Heart Disease



Laurence Sperling, M.D.
, Emory University School of Medicine, Atlanta, GA, USA


Appropriate intensity statins are recommended by the ACC/ AHA Blood Cholesterol Guidelines as first line lipid therapy for both high risk secondary prevention patients with established atherosclerotic cardiovascular disease (ASCVD) and post-acute coronary syndrome (ACS). The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is the first randomized prospective clinical outcomes trial to demonstrate that stain therapy plus a non-statin agent (ezetimibe) reduced ASCVD events (6.4% relative risk reduction of the primary composite endpoint). It is likely this study will impact future guideline recommendations. Despite established benefits of statin therapy for secondary prevention there appears to be substantial underutilization of well-validate guideline-directed therapies, and a significant lack of medication adherence. Strategies to assess gaps in care delivery, improve awareness of guideline-driven recommendations, and patient adherence to therapies may be more important ways to IMPROVE-IT.



©1998-2016 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.